Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AMED

Amedisys (AMED) Stock Price, News & Analysis

Amedisys logo

About Amedisys Stock (NASDAQ:AMED)

Key Stats

Today's Range
$100.93
$101.02
50-Day Range
$96.91
$101.01
52-Week Range
$82.15
$101.02
Volume
1.06 million shs
Average Volume
780,222 shs
Market Capitalization
$3.32 billion
P/E Ratio
39.30
Dividend Yield
N/A
Price Target
$100.50
Consensus Rating
Moderate Buy

Company Overview

Amedisys Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

AMED MarketRank™: 

Amedisys scored higher than 41% of companies evaluated by MarketBeat, and ranked 739th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amedisys has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside/Downside

    The consensus price target for Amedisys is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Amedisys has received no research coverage in the past 90 days.

  • Read more about Amedisys' stock forecast and price target.
  • Earnings Growth

    Earnings for Amedisys are expected to grow by 10.00% in the coming year, from $4.40 to $4.84 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amedisys is 39.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 282.56.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amedisys is 39.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.98.

  • Price to Earnings Growth Ratio

    Amedisys has a PEG Ratio of 1.34. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Amedisys has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Amedisys' valuation and earnings.
  • Short Interest

    There is no current short interest data available for AMED.
  • Dividend Yield

    Amedisys does not currently pay a dividend.

  • Dividend Growth

    Amedisys does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for AMED.
    • Insider Buying vs. Insider Selling

      In the past three months, Amedisys insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 2.10% of the stock of Amedisys is held by insiders.

    • Percentage Held by Institutions

      94.36% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Amedisys' insider trading history.
    Receive AMED Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    AMED Stock News Headlines

    Why UnitedHealth (UNH) Stock Is Trading Up Today
    Protect Your Bank Account with THESE 4 Simple Steps
    Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.tc pixel
    UnitedHealth Leaps on Medicare Star Ratings
    UnitedHealth Surges on Medicare Bonus Outlook
    See More Headlines

    AMED Stock Analysis - Frequently Asked Questions

    Amedisys, Inc. (NASDAQ:AMED) posted its quarterly earnings results on Tuesday, July, 29th. The health services provider reported $1.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.39 by $0.15. The firm's quarterly revenue was up 5.2% on a year-over-year basis.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Amedisys investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

    Company Calendar

    Last Earnings
    7/29/2025
    Today
    10/01/2025
    Next Earnings (Estimated)
    11/05/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - OUTP/HM CRE
    Sub-Industry
    Health Care Services
    Current Symbol
    NASDAQ:AMED
    CIK
    896262
    Employees
    20,000
    Year Founded
    1982

    Price Target and Rating

    High Price Target
    $101.00
    Low Price Target
    $100.00
    Potential Upside/Downside
    -0.5%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    2 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    $2.57
    Trailing P/E Ratio
    39.30
    Forward P/E Ratio
    22.96
    P/E Growth
    1.34
    Net Income
    $43.23 million
    Net Margins
    3.56%
    Pretax Margin
    6.21%
    Return on Equity
    12.91%
    Return on Assets
    7.29%

    Debt

    Debt-to-Equity Ratio
    0.26
    Current Ratio
    1.36
    Quick Ratio
    1.36

    Sales & Book Value

    Annual Sales
    $2.40 billion
    Price / Sales
    1.38
    Cash Flow
    $6.24 per share
    Price / Cash Flow
    16.20
    Book Value
    $38.77 per share
    Price / Book
    2.61

    Miscellaneous

    Outstanding Shares
    32,887,000
    Free Float
    32,196,000
    Market Cap
    $3.32 billion
    Optionable
    Optionable
    Beta
    0.89

    Social Links

    These 7 Stocks Will Be Magnificent in 2025 Cover

    Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

    Get This Free Report

    This page (NASDAQ:AMED) was last updated on 10/2/2025 by MarketBeat.com Staff
    From Our Partners